157 related articles for article (PubMed ID: 36351652)
21. [Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness].
Basire A; Picard C
Transfus Clin Biol; 2014 Nov; 21(4-5):193-206. PubMed ID: 25277423
[TBL] [Abstract][Full Text] [Related]
22. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Naper C; Tjønnfjord GE; Njerve IU; Ezligini F; Landmark BF; Meinke S; Sandgren P; Höglund P; Hetland G
Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
[TBL] [Abstract][Full Text] [Related]
23. [Development of iPS cell-derived blood products and production guidelines].
Sugimoto N; Eto K
Rinsho Ketsueki; 2017; 58(10):2150-2159. PubMed ID: 28978860
[TBL] [Abstract][Full Text] [Related]
24. [Novel physico-chemical regulation mechanism enables the production of 100 billion platelets].
Nakamura S; Eto K
Rinsho Ketsueki; 2020; 61(6):628-633. PubMed ID: 32624536
[TBL] [Abstract][Full Text] [Related]
25. A case of platelet transfusion refractoriness due to anti-CD36 with a successful treatment outcome.
Khatri SS; Curtis BR; Yamada C
Immunohematology; 2019 Dec; 35(4):139-144. PubMed ID: 31935329
[TBL] [Abstract][Full Text] [Related]
26. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin.
Bakchoul T; Bassler D; Heckmann M; Thiele T; Kiefel V; Gross I; Arnold DM; DiTomasso J; Smith JW; Paes B; Greinacher A
Transfusion; 2014 Mar; 54(3):640-5. PubMed ID: 23869512
[TBL] [Abstract][Full Text] [Related]
27. Silencing of p53 and CDKN1A establishes sustainable immortalized megakaryocyte progenitor cells from human iPSCs.
Sone M; Nakamura S; Umeda S; Ginya H; Oshima M; Kanashiro MA; Paul SK; Hashimoto K; Nakamura E; Harada Y; Tsujimura K; Saraya A; Yamaguchi T; Sugimoto N; Sawaguchi A; Iwama A; Eto K; Takayama N
Stem Cell Reports; 2021 Dec; 16(12):2861-2870. PubMed ID: 34861163
[TBL] [Abstract][Full Text] [Related]
28. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
Gras C; Schulze K; Goudeva L; Guzman CA; Blasczyk R; Figueiredo C
Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
[TBL] [Abstract][Full Text] [Related]
29. [Progress towards development of a platelet transfusion product employing iPS cells].
Suzuki D; Eto K
Rinsho Ketsueki; 2016 Mar; 57(3):308-14. PubMed ID: 27076243
[TBL] [Abstract][Full Text] [Related]
30. Establishment of platelet donor registry improves the treatment of platelet transfusion refractoriness in Guangzhou region of China.
Xia WJ; Ye X; Tian LW; Xu XZ; Chen YK; Luo GP; Bei CH; Deng J; Santoso S; Fu YS
Transfus Med; 2010 Aug; 20(4):269-74. PubMed ID: 20136782
[TBL] [Abstract][Full Text] [Related]
31. [Study of the platelet GP specific antibodies and HLA antibodies expression in platelet transfusion refractoriness patients].
Xia WJ; Ye X; Deng J; Chen YK; Xu XZ; Ding HQ; Luo GP; Fu YS
Zhonghua Xue Ye Xue Za Zhi; 2010 Sep; 31(9):594-8. PubMed ID: 21122318
[TBL] [Abstract][Full Text] [Related]
32. Selective Inhibition of ADAM17 Efficiently Mediates Glycoprotein Ibα Retention During Ex Vivo Generation of Human Induced Pluripotent Stem Cell-Derived Platelets.
Hirata S; Murata T; Suzuki D; Nakamura S; Jono-Ohnishi R; Hirose H; Sawaguchi A; Nishimura S; Sugimoto N; Eto K
Stem Cells Transl Med; 2017 Mar; 6(3):720-730. PubMed ID: 28297575
[TBL] [Abstract][Full Text] [Related]
33. Analysis of platelet-reactive alloantibodies and evaluation of cross-match-compatible platelets for the management of patients with transfusion refractoriness.
Wang J; Xia W; Deng J; Xu X; Shao Y; Ding H; Chen Y; Liu J; Chen D; Ye X; Santoso S
Transfus Med; 2018 Feb; 28(1):40-46. PubMed ID: 28516675
[TBL] [Abstract][Full Text] [Related]
34. Longitudinal management with crossmatch-compatible platelets for refractory patients: alloimmunization, response to transfusion, and clinical outcomes (CME).
Wiita AP; Nambiar A
Transfusion; 2012 Oct; 52(10):2146-54. PubMed ID: 23113654
[TBL] [Abstract][Full Text] [Related]
35. A novel bioreactor and culture method drives high yields of platelets from stem cells.
Avanzi MP; Oluwadara OE; Cushing MM; Mitchell ML; Fischer S; Mitchell WB
Transfusion; 2016 Jan; 56(1):170-8. PubMed ID: 26467770
[TBL] [Abstract][Full Text] [Related]
36. Quantitation of coated platelet potential during collection, storage, and transfusion of apheresis platelets.
Charania R; Smith J; Vesely SK; Dale GL; Holter J
Transfusion; 2011 Dec; 51(12):2690-4. PubMed ID: 21645004
[TBL] [Abstract][Full Text] [Related]
37. Expandable megakaryocyte cell lines enable clinically applicable generation of platelets from human induced pluripotent stem cells.
Nakamura S; Takayama N; Hirata S; Seo H; Endo H; Ochi K; Fujita K; Koike T; Harimoto K; Dohda T; Watanabe A; Okita K; Takahashi N; Sawaguchi A; Yamanaka S; Nakauchi H; Nishimura S; Eto K
Cell Stem Cell; 2014 Apr; 14(4):535-48. PubMed ID: 24529595
[TBL] [Abstract][Full Text] [Related]
38. Development of platelet replacement therapy using human induced pluripotent stem cells.
Nakamura S; Sugimoto N; Eto K
Dev Growth Differ; 2021 Feb; 63(2):178-186. PubMed ID: 33507533
[TBL] [Abstract][Full Text] [Related]
39. Generation and characterization of HLA-universal platelets derived from induced pluripotent stem cells.
Norbnop P; Ingrungruanglert P; Israsena N; Suphapeetiporn K; Shotelersuk V
Sci Rep; 2020 May; 10(1):8472. PubMed ID: 32439978
[TBL] [Abstract][Full Text] [Related]
40. Generation of HLA-deficient platelets from hematopoietic progenitor cells.
Figueiredo C; Goudeva L; Horn PA; Eiz-Vesper B; Blasczyk R; Seltsam A
Transfusion; 2010 Aug; 50(8):1690-701. PubMed ID: 20412529
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
